Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Salicylic acid 6% in White soft paraffin
1305020S0AADEDE
|
Salicylic acid (Psoriasis) | Salicylic acid | Skin | No data available |
|
Salicylic acid 6% in Yellow soft paraffin
1305020S0AADQDQ
|
Salicylic acid (Psoriasis) | Salicylic acid | Skin | No data available |
|
Salicylic acid 70% in White soft paraffin
1305020S0AACNCN
|
Salicylic acid (Psoriasis) | Salicylic acid | Skin | No data available |
|
Salicylic acid 8% in White soft paraffin
1305020S0AACLCL
|
Salicylic acid (Psoriasis) | Salicylic acid | Skin | No data available |
|
Salicylic acid and Sulfur cream BPC 1968
1306010T0AAAAAA
|
Sulfur (Topical) | Sulfur | Skin | No data available |
|
Salicylic acid powder
190400000AACCCC
|
Generic compound preparation BNF 1904000 | Other single substance preparations | Other Drugs and Preparations | No data available |
|
Saline nebuliser liquid 20ml unit dose Steripoule vials
1202020L0BJAABE
|
Saline Steripoule (Galen) | Sodium chloride | Ear, Nose and Oropharynx | No data available |
|
Salinum liquid
21210000001
|
Salinum liquid | Dry Mouth Products | Appliances | No data available |
|
Salipraneb 0.5mg/2.5mg nebuliser soln 2.5ml amp (Actavis)
0301040R0BEAAAC
|
Salipraneb (Actavis) | Salbutamol | Respiratory System | No data available |
|
Salipraneb 0.5mg/2.5mg nebuliser soln 2.5ml ampoules (Arrow)
0301040R0BDAAAC
|
Salipraneb (Arrow) | Salbutamol | Respiratory System | No data available |
|
Salivace spray
1203050A0BHAAAJ
|
Salivace | Artificial saliva products | Ear, Nose and Oropharynx | No data available |
|
Salmeterol 50microgram inhalation pdr blist with device
0301011U0AAAAAA
|
Salmeterol | Salmeterol | Respiratory System | No data available |
|
Salmeterol 50microgram inhalation powder blisters
0301011U0AAABAB
|
Salmeterol | Salmeterol | Respiratory System | No data available |
|
Salonpas medicated plasters
100302000BBBTA0
|
Proprietary compound preparation BNF 1003020 | Other rubefacient and topical antirheumatic preparations | Musculoskeletal and Joint Diseases | No data available |
|
Saltair ileostomy night belt
23304103017
|
Saltair ileostomy night belt | Belts | Stoma Appliances | No data available |
|
Saltair made to measure ileostomy girdle
23304103009
|
Saltair made to measure ileostomy girdle | Belts | Stoma Appliances | No data available |
|
Saltair twin pack large
23854108503
|
Saltair twin pack large | Skin Protectors | Stoma Appliances | No data available |
|
Saltair twin pack small
23854108502
|
Saltair twin pack small | Skin Protectors | Stoma Appliances | No data available |
|
Salts female support briefs extra small white
23304103044
|
Salts female support briefs extra small white | Belts | Stoma Appliances | No data available |
|
Salts ostomy cleaning soap
23804108010
|
Salts ostomy cleaning soap | Skin Fillers And Protectives | Stoma Appliances | No data available |
|
Samsca 30mg tablets
0605020Y0BBABAB
|
Samsca | Tolvaptan | Endocrine System | No data available |
|
Sanatogen Baby syrup
090607000BBECA0
|
Proprietary compound preparation BNF 0906070 | Other multivitamin preparations | Nutrition and Blood | No data available |
|
Sanatogen High Protein powder
091101000BBQCA0
|
Proprietary compound preparation BNF 0911010 | Other amino acidandnutritional agent preparations | Nutrition and Blood | No data available |
|
Sanatogen Mother to be tablets
091000000BBWDBU
|
Proprietary compound preparation BNF 0910000 | Other compound vitamin/mineral formulation preparations | Nutrition and Blood | No data available |
|
Sandimmun 250mg/5ml concentrate for inf ampoules
0802020G0BBABAE
|
Sandimmun | Ciclosporin | Malignant Disease and Immunosuppression | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.